29 results about "Antigen delivery" patented technology

A spore of a bacillus subtilis B.subtilis WB600 strain is used as an antigen delivery carrier, spore coat protein C (CotC) is used as anchoring protein, a key protein ATPase gene and a CotC gene of micropterus salmoides iridovirus are fused through a gene fusion technology, a recombinant spore surface display system is constructed, the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. After being orally applied to fishes, the vaccine can tolerate the gastrointestinal tract environment and is accurately delivered to intestinal related lymphatic tissues to stimulate fish immunity, and finally prevention and control of the iridovirus of the micropterus salmoides are achieved.

The invention provides an allosteric nanogel adjuvant as well as a preparation method and application thereof, and belongs to the technical field of vaccines. The allosteric nanogel adjuvant comprises a self-assembly motif, a responsive site and an immunomodulatory peptide fragment, and the self-assembly motif is composed of 2-5 amino acids; the allosteric nanogel adjuvant has a structure as shown in a formula I, and is named as NTP5 for short; the allosteric nanogel adjuvant is self-assembled into nanoparticles, the nanoparticles are allosteric into a nanofiber structure through responsive broken bonds, nanogel is further formed, and the key problems of a traditional vaccine in the aspects of antigen delivery and immune activation are effectively solved. The nanogel adjuvant can efficiently load various antigens to form a stable nano vaccine, activate an immune microenvironment and provide more means and thoughts for vaccine development.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The present invention relates to a conjugate comprising an mRNA of an antigen protein and an mRNA encoding a carrier protein linked to the 5'terminal and the 3 'terminal of the mRNA of the antigen protein, and an vaccination composition and / or a vaccine composition comprising the conjugate, the present invention having an effect of stably increasing the expression of an antigen protein.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

The application discloses a kind of based on HIV envelope protein chimeric exosome and its preparation method and application, belong to biological medicine technical field.The application first constructs the cell line of stable expression HIV envelope protein Env, obtains engineered exosome from cell culture supernatant separation and purification;The exosome is used as immunogen combined with adjuvant immunization experimental animal, and high-efficiency induction specific humoral immune response;Again, obtain Env antigen specificity single B cell by flow cytometry sorting, obtain antibody variable region gene by single cell lysis, reverse transcription and nest PCR amplification, cloning to expression vector and expressing in mammalian cell, finally, HIV specific neutralizing antibody is screened by binding activity, affinity and neutralizing activity;The application is combined with single B cell antibody screening technology by embedding HIV Env antigen in the form of membrane combination in exosome surface, and realizes the synergistic optimization of antigen delivery and antibody screening process.

The present application relates to the technical field of medicine, in particular to a functional nanomaterial based on choline phosphate-cell membrane interaction and application thereof.The present application modifies manganese mineralized black phosphorus nanomaterial by bio-inspired polymer pGluCP adsorption, which retains the excellent biocompatibility and photothermal performance of BP, and at the same time, pGluCP enhances the 'chassis' effect of the material, captures tumor-related antigens, and can simultaneously capture water-soluble antigens and water-insoluble membrane antigens and form pathogen-like micro-nanoparticles, which is helpful for antigen delivery and APC presentation, and provides a feasible tool for capturing non-water-soluble membrane antigens, which is a major challenge.MnBP and pGluCP synergistically act, and can realize the personalized conversion of autologous tumors to vaccine production and delivery.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

The present application relates to the technical field of tumor immunotherapy. The present application provides a responsive antigen capture nano platform, a preparation method and application thereof. The product of the present application is applied by systemic administration such as intravenous injection; can specifically respond to peroxynitrite in the tumor microenvironment, realize the precise activation of the tumor site; can covalently capture tumor-related antigens through high efficiency, deliver the antigens to antigen presenting cells, so as to enhance the anti-tumor immune response; combined with photodynamic therapy can significantly inhibit tumor growth.

The invention relates to an oral nano traditional Chinese medicine antigen delivery system as well as a construction method and application thereof, and belongs to the technical field of oral nano materials. The construction method comprises the following steps: (1) preparing an OM nanoparticle suspension; (2) preparing a cationic liposome suspension; (3) preparing an OM / BF loaded cationic liposome suspension; and (4) constructing an oral nano traditional Chinese medicine antigen delivery system. According to the invention, multiple barriers of gastrointestinal tracts are broken through, the bioavailability of drugs is improved, precise immune tracking is realized through an OVA tumor antigen model, and in-vivo anti-tumor CTL reaction is simulated, so that an anti-tumor effect is synergistically exerted on three levels of a cell level, a tissue level and an immune level; according to the preparation method, the problems of poor water solubility and low delivery efficiency of bufalin serving as a traditional Chinese medicine active ingredient are effectively solved, meanwhile, through macrophage-mediated immunoregulation and accurate drug release, the targeting property and the treatment efficiency are improved, and a new way is opened up for tumor immunotherapy of oral nano traditional Chinese medicines.

In one aspect, the disclosure relates to recombinant bacterial vectors including a gene encoding at least one antigen from Aeromonas hydrophila or tilapia lake virus, methods of making the same, vaccines incorporating the same, and methods of inducing an immune response in the subject and / or preventing infection by a pathogen in the subject using the same. In one aspect, the subject is a fish in an aquaculture system. In an aspect, the vector or vaccine can be administered by bath immersion or intracoelomic injection and, in some cases, can confer protection against an additional pathogen such as, for example, Edwardsiella piscicida. In any of these aspects, the vectors are susceptible to antibiotics and do not persist in the environment.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

The present disclosure provides improved peptide tag moieties with affinity for binding molecules. The peptide tag moieties are useful, for example, as part of tag constructs, together with cargo moieties. They offer unexpected advantages as part of biopharmaceutical product conjugates compared to known tag moieties with similar amino acid sequences. Also disclosed are binding molecules and bispecific conjugates with affinity for the peptide tag moieties, as well as conjugates comprising a peptide tag moiety non-covalently bound to such binding molecules or bispecific conjugates. In such conjugates, the tag moiety can form part of a tag construct that further comprises an antigen as a cargo moiety, for example, for antigen delivery to immune cells. Medical uses of the tag moieties, tag constructs, and conjugates of the present disclosure are also provided.

Provided is a binding protein that binds CD40 and is an agonist thereof. In a particular embodiment the invention provides an agonistic anti-CD40 antibody. Also provided are bispecific conjugates comprising the binding protein, and complexes comprising the bispecific conjugates non-covalently bound to a tag construct comprising an antigen, for antigen delivery to immune cells. Medical uses of the binding proteins, conjugates and complexes of the invention are also provided.

The application discloses a kind of synthesis method of spherical polymer nanoparticles, it is related to vaccine technical field, and the method comprises the following steps: polyvinylpyrrolidone is dissolved in mixed solvent, then glyoxal, ascorbic acid and ethylenediamine are added in turn respectively, after stirring for a certain time, the color of solution obviously changes from yellowish to wine red.The solution containing prepolymer is transferred into reaction kettle, the reaction kettle is put into oven to react, the previous prepolymer will further crosslink and polymerize, form nonlinear network polymer skeleton, through repeated centrifugation and ethanol washing, finally drying can obtain the target spherical nanoparticle material.The application uses ascorbic acid as raw material, ethylenediamine as initiator and connecting agent, glyoxal as crosslinking agent, successfully synthesizes a kind of brand-new polymer nanoparticle, simultaneously realizes efficient antigen delivery and specific activation B cell, and is a kind of brand-new ideal vaccine adjuvant with promising application.

The present invention relates to a fusion protein comprising a peptide antigen and a human thioredoxin protein linked to the N-terminus, C-terminus, or both, of the peptide antigen, wherein all cysteine ​​residues in the amino acid sequence of the human thioredoxin protein have been substituted with non-cysteine ​​residues; a nucleic acid molecule encoding the fusion protein; an expression vector comprising the nucleic acid molecule; a cell transformed with the expression vector; and a composition comprising the fusion protein, nucleic acid molecule, expression vector, or cell.

The application discloses a fluorine-nitrogen modified high-molecular immunoadjuvant material, a preparation method and application thereof, and belongs to the technical field of high-molecular materials and immunology, wherein the high-molecular immunoadjuvant material comprises a biodegradable polycarbonate main chain, and polyethylene glycol segments, perfluoroalkyl side chains and nitrogen-containing seven-membered ring side chains connected to the polycarbonate main chain. The perfluoroalkyl side chains are introduced to promote antigen delivery and improve the antigen presenting cell uptake efficiency; the nitrogen-containing seven-membered ring side chains are introduced to the side chains to make the material have intracellular environment response characteristics, so that the antigen intracellular release process is improved and the antigen utilization efficiency is improved. In addition, the polycarbonate which can be completely degraded by enzymes in the body is used as the main chain framework, so that the material has good delivery performance and biological safety.

Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and / or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides that may be conjugated to immunogens and have the ability to self-assemble into immunogen-displaying nanofilaments that activate the humoral and cellular immune responses. The self-assembling polypeptide comprises an amino acid sequence having at least 60% identity with the sequence of the R4 and R5 domains from a Curli-specific gene A (CsgA) protein. The present application also relates to nucleic acids encoding the self-assembling polypeptide / immunogen conjugates, to compositions and vaccines comprising the self-assembling polypeptide / immunogen conjugates or nucleic acids, as well as to methods for inducing an immune response against an immunogen and / or for preventing and / or treating a microbial infection, cancer or any pathological conditions in which vaccination may be useful such as autoimmune diseases and allergies, in a subject.

The present disclosure provides improved binding molecules comprising an immunoglobulin-binding domain with affinity for a peptide tag moiety. The binding molecules are useful, for example, as part of a bispecific conjugate. They offer unexpected advantages as part of a biopharmaceutical product when compared with known binding molecules with similar binding affinities. Also provided are bispecific conjugates comprising the binding molecules, and complexes comprising the bispecific conjugates non-covalently linked to tag constructs comprising a peptide tag moiety and a cargo moiety comprising an antigen, for antigen delivery to immune cells. Medical uses of the binding molecules, conjugates, and complexes of the present disclosure are also provided.

The invention discloses a self-adjuvant gel and an application of the self-adjuvant gel in tumor immunotherapy. According to the gel, N-acetylcysteine (NAC) is grafted with chitosan to form a sulfydryl-containing functional carrier, and the activity of T cells is effectively maintained by utilizing the interaction between NAC and sulfydryl on the surfaces of the T cells; meanwhile, the oxidized beta-glucan has Toll-like receptor 4 activation capability, and can promote the maturation and activation of dendritic cells. The formation of the gel depends on a Schiff base reaction between an aldehyde group in the oxidized beta-glucan and an amino group of the chitosan, and self-assembly gel formation under a mild condition is realized. The system can load a chemotactic factor CXCL9 and a tumor antigen at the same time, efficient recruitment of T cells is achieved by continuously releasing the CXCL9, and the antigen is synchronously and slowly released to induce specific immune response. The self-adjuvant gel has the functions of immune cell recruitment, antigen delivery and immune activation, and provides a novel material platform and strategy for tumor immunotherapy.

The invention relates to an application of an activity regulating cytoskeleton associated protein (ARC) in an REV nanoparticle vaccine and the vaccine, and belongs to the technical field of animal vaccine preparation, the amino acid sequence of the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3, the nucleotide sequence is shown as SEQ ID NO.4, and the activity regulating cytoskeleton associated protein (ARC) is shown as SEQ ID NO.3. The activity regulation cytoskeleton associated protein is used as a carrier protein in a nanoparticle vaccine, and the nanoparticle vaccine is an REV nanoparticle vaccine. The ARC is used as a carrier in the nanoparticle vaccine for the first time to be self-assembled into nanoparticles, and the nanoparticles can serve as an antigen delivery platform, play a protein-antigen delivery role and stimulate an organism to generate immune response.

The present invention relates to: a fusion protein comprising a peptide antigen and a human thioredoxin protein linked to the N-terminus, the C-terminus or both of the peptide antigen, wherein all cysteine residues in the amino acid sequence of the human thioredoxin protein are substituted with non-cysteine residues; a nucleic acid molecule encoding the fusion protein; an expression vector comprising the nucleic acid molecule; a cell transformed with the expression vector; and a composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

The invention relates to the crossing field of biological nanometer technology, immune engineering and drug delivery, and discloses a topological structure programmable antigen delivery system based on a DNA nanometer frame and a construction method of the topological structure programmable antigen delivery system. The antigen delivery system comprises at least one DNA nano frame with a specific three-dimensional topological structure; the antigen molecule and / or the immunologic adjuvant are / is accurately modified on the DNA nano-framework through covalent or non-covalent interaction; wherein the topological structure of the DNA nano framework is selected from at least one of a small icosahedron framework S-DIF, a truncated icosahedron framework DSF, an octahedron framework DOF and a large icosahedron framework L-DIF. According to the invention, the rational association between the carrier topology and the immune function is realized, the efficiency bottleneck of cross presentation is broken through, a multifunctional integrated platform with synergistic interaction is provided, and the DNA material is natural and degradable, has high biocompatibility, and has high efficiency and biological safety.

The present application belongs to the field of fish molecular immunology, and particularly relates to an oral vaccine containing a largemouth bass iridovirus ATPase and a preparation method thereof. B. subtilis The spores of the WB600 strain are antigen delivery carriers, the spore coat protein C (CotC) is used as an anchor protein, and the key protein of the largemouth bass iridovirus is fused with the ATPase gene and CotC the gene to construct a recombinant spore surface display system, so that the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. The vaccine can tolerate the gastrointestinal environment after being orally administered to fish, and is accurately delivered to the gut-associated lymphoid tissue to stimulate the immunity of the fish, so that the prevention and control of the largemouth bass iridovirus is finally achieved.

The present invention relates to calsequestrin-based metal ion reactive particles and their applications. More specifically, the invention concerns calsequestrin-based metal ion reactive particles, which are prepared by combining bioactive substances frequently used in pharmaceuticals and cosmetics with calsequestrin (CSQ) and then reacting them with metal ions. This invention also relates to the use of these particles as drug delivery carriers, pharmaceutical compositions, or vaccines. The metal ion reactive particles according to the present invention can enhance the in vivo and in vitro stability of bioactive substances, prolong their active duration, increase their half-life in the body, and improve antigen delivery efficiency.

Developing an effective HIV-1 vaccineis contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, vaccine candidates such as LC3.SOSIP(w) and LC3.SOSIP(s) showed promising results in New Zealand white rabbits. These candidates elicited significantly higher Env-specific IgG levels than controls, demonstrated high affinity for SOSIP antigens in ELISA binding assays, and achieved broad neutralizing capabilities against multiple HIV-1 pseudoviruses in TZM-bl neutralization assays. In conclusion, HIV Env antigen can be adaptively targeted to LC as a trimer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such constructs as LC targeting HIV-1 vaccines.

The invention belongs to the technical field of biological vaccine preparation, and particularly relates to a preparation method of a targeted antigen displayed MS2 phage VLPs nanoparticle vaccine. The preparation method sequentially comprises the following steps: preparation and activation of a targeting ligand, fixed-point transformation and expression of MS2 bacteriophage capsid protein, preparation of targeting antigen-aptamer fusion protein, folding optimization and activity pre-verification of the antigen-aptamer fusion protein, self-assembly and antigen display of targeting MS2-VLPs, purification and characterization of targeting VLPs nanoparticles, and preparation of the vaccine preparation. On the basis, by introducing the targeting ligand aiming at the specific receptor on the surface of the antigen presenting cell, accurate recognition and combination of the VLPs vaccine on the target cell are realized, the problem that the antigen display lacks targeting is fundamentally solved, the antigen delivery efficiency is remarkably improved, the off-target effect is effectively reduced, and the antigen waste is avoided.